SRPT - Sarepta Therapeutics - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8036071004

Gene therapies, RNA-targeted therapeutics, Muscular dystrophy treatments

Sarepta Therapeutics Inc. is a biopharmaceutical company that specializes in developing innovative treatments for rare diseases. The company's primary focus is on RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities.

One of Sarepta's flagship products is EXONDYS 51, an injection used to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the dystrophin gene that can be treated with exon 51 skipping. The company also offers VYONDYS 53, which treats DMD in patients with a confirmed mutation of the dystrophin gene that can be treated with exon 53 skipping. Additionally, Sarepta has developed AMONDYS 45, a treatment for DMD in patients with a confirmed mutation of the dystrophin gene.

Sarepta is also working on ELEVIDYS, an adeno-associated virus-based gene therapy for ambulatory pediatric patients aged 4-5 years with DMD and a confirmed mutation in the dystrophin gene. The company's pipeline includes SRP-5051, a peptide-conjugated phosphorodiamidate morpholino oligomer (PMO) that binds to exon 51 of dystrophin pre-mRNA, and SRP-9003, a gene therapy program for limb-girdle muscular dystrophies.

Sarepta has formed partnerships with several organizations, including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Genevant Sciences, University of Florida, Dyno Therapeutics, Hansa Biopharma, Duke University, Genethon, and StrideBio, to advance its research and development efforts.

Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts. For more information, visit their website at https://www.sarepta.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for SRPT - Sarepta Therapeutics  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for SRPT - Sarepta Therapeutics  - Stock & Dividends

SRPT Stock Overview

Market Cap in USD 14,871m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1997-06-03

SRPT Stock Ratings

Growth 5y 10.8
Fundamental -43.1
Dividend 0.00
Rel. Performance vs Sector 0.88
Analysts 4.41/5
Fair Price Momentum 137.25 USD
Fair Price DCF -

SRPT Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

SRPT Growth Ratios

Growth 12m 37.54%
Growth Correlation 12m 47%
Growth Correlation 3m 24%
CAGR 5y 0.12%
CAGR/Mean DD 5y 0.00
Sharpe Ratio 12m 0.51
Alpha vs SP500 12m 19.63
Beta vs SP500 5y weekly 0.71
ValueRay RSI 40.76
Volatility GJR Garch 1y 56.13%
Price / SMA 50 6.77%
Price / SMA 200 23.4%
Current Volume 1435.3k
Average Volume 20d 2233.1k

External Links for SRPT Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of SRPT stocks?
As of July 21, 2024, the stock is trading at USD 145.61 with a total of 1,435,320 shares traded.
Over the past week, the price has changed by -4.27%, over one month by +17.90%, over three months by +25.94% and over the past year by +39.35%.
What are the forecast for SRPT stock price target?
According to ValueRays Forecast Model, SRPT Sarepta Therapeutics will be worth about 151 in July 2025. The stock is currently trading at 145.61. This means that the stock has a potential upside of +3.71%.
Issuer Forecast Upside
Wallstreet Target Price 196.3 34.8
Analysts Target Price 180.6 24.0
ValueRay Target Price 151 3.71